A Phase Ⅱ Clinical Study of Sanhuangjingshimingwan in Wet( Neovascular)Age-related Macular Degeneration(wAMD) Subjects
A Randomized, Double-blind, Placebo-controlled, Ranibizumab Injected, Multicenter Phase II Clinical Study on the Efficacy and Safety of Sanhuangjingshimingwan in the Wet AMD(Qi and Yin Deficiency, Phlegm-blood Stasis Syndrome )Subjects
Sponsor: Tasly Pharmaceutical Group Co., Ltd
A PHASE2 clinical study on Age-related Macular Degeneration, this trial is completed. The trial is conducted by Tasly Pharmaceutical Group Co., Ltd and has accumulated 7 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Nov 2022 — Dec 2022 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Nov 2022 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE2
First recorded
Jul 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tasly Pharmaceutical Group Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .